Feature | November 07, 2013

PROSPECT II Clinical Trial to Examine Preemptive Bioresorbable Stenting of Vulnerable Plaques

stents bioresorbable cath lab intravascular imaging clinical trial study abbott
November 7, 2013 — The Cardiovascular Research Foundation (CRF) and the Uppsala Clinical Research Center (UCR) of Uppsala, Sweden announced the initiation of the Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT II) trial and the PROSPECT ABSORB sub study. PROSPECT II is an investigator-initiated multicenter, prospective registry study that will assess the ability of intracoronary near infrared spectroscopy (NIRS) to identify non-flow obstructing vulnerable plaques that subsequently lead to coronary events. PROSPECT ABSORB is an investigator-initiated multicenter, randomized trial that will, for the first time, evaluate the ability of a bioresorbable scaffold to safely increase luminal dimensions of vulnerable plaque.
 
The PROSPECT II study will enroll 900 patients with acute coronary syndrome (ACS) and will be led by Gregg Stone M.D., professor of medicine, College of Physicians and Surgeons, Columbia University, New York, director, Cardiovascular Research and Education, Center for Interventional Vascular Therapy, NewYork-Presbyterian Hospital/Columbia University Medical Center and co-director, Medical Research and Education Division, CRF and David Erlinge, M.D, Ph.D., director, department of cardiology, Lund University, Skane University Hospital, Lund, Sweden. Patient enrollment will begin in the first part of 2014 and be completed in approximately one year. The study will be conducted in approximately 16 sites in Scandinavia.
 
Each patient will be examined with intravascular ultrasound (IVUS) and NIRS in all three coronary arteries. In the PROSPECT ABSORB sub study, 300 patients with a plaque at high risk of causing future coronary events, as shown in the original PROSPECT study (plaque burden ? 70 percent), will be randomized to treatment with Abbott Vascular’s Absorb Bioresorbable Vascular Scaffold (BVS) plus guideline directed medical therapy (GDMT) or GDMT alone, with each patient undergoing angiography and IVUS/NIRS after two years.  All 900 patients will be measured at baseline and then followed in the registry for at least three years to detect the occurrence of coronary events. 
 
The integrated PROSPECT II and PROSPECT ABSORB study program is being funded by grants from InfraReDx, The Medicines Company and Abbott. Uppsala Clinical Research Center (UCR) will have the operational responsibility and be the sponsor of the study. The study will be conducted in academic partnership with the CRF Clinical Trials Center (CTC).
 
Data from the original PROSPECT trial demonstrated for the first time prospectively that vulnerable plaques that are most likely to cause sudden unexpected adverse cardiac events can be identified through imaging techniques months to years before the adverse events occur. These study findings were published in the Jan. 20, 2011 issue of the New England Journal of Medicine.
 
“Using the NIRS imaging technology to detect lipid rich plaque (LRP) has been an eye-opener for us. We can see in vivo that close to all patients with a ST-elevation myocardial infarction (STEMI) exhibit a LRP at the culprit site. In PROSPECT II we will determine the importance of LRP prospectively so that in the future, we can hopefully identify and treat the vulnerable plaque before the infarction happens,” said Erlinge.
 
“Findings from the original PROSPECT study have helped physicians identify those lesions that are at especially high risk of causing future adverse cardiovascular events using a combination of imaging modalities based on IVUS,” said Stone.
 
“NIRS has been extremely well validated for detecting lipid, which is at the core of most vulnerable plaques. PROSPECT II will determine the ability of NIRS to identify these high-risk lesions in an adequately powered prospective study. And PROSPECT ABSORB will, for the first time, test the feasibility of an interventional approach in preventing future major adverse cardiovascular events arising from plaques, which appear angiographically innocuous (and are thus not currently stented), but are in fact the source of future acute coronary syndromes. This is truly a groundbreaking investigation.”
 
For more information: www.crf.org, www.ucr.uu.se

Related Content

Arterys, Cardiac MRI, cardiac MRI advances

An example of the Artery's blood flow imaging assessment software that can help automate cardiac MRI. 

Feature | Cardiac Imaging| January 16, 2017 | Dave Fornell
Each year imaging system manufacturers use the Radiological Society of North America (RSNA) meeting at the end of the
BioTrace Medical, first U.S. patients, Tempo Temporary Pacing Lead, EP lab, TAVR
News | Leads Implantable Devices| January 13, 2017
BioTrace Medical Inc. announced in December the first commercial use of the company’s Tempo Temporary Pacing Lead since...
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Sponsored Content | Videos | Cardiovascular Ultrasound| January 13, 2017
Detailed imaging is needed to support complex interventions for the assessment and procedure guidance.
ACIST-FFR Study, enrollment complete, Navvus catheter, fractional flow reserve
News | FFR Catheters| January 12, 2017
Acist Medical Systems Inc. announced that enrollment is complete for its Fractional Flow Reserve (FFR) Study –...
updated classification system, heart attack risk, Mount Sinai, Johns Hopkins, Journal of the American College of Cardiology, JACC
News | Cardiac Diagnostics| January 12, 2017
Experts at Johns Hopkins and New York's Mount Sinai Health System have published a suggested new plan for a five-stage...
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents| January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
atrial fibrillation patients, warfarin therapy, medication adherence, University of Michigan study, JAMA Cardiology
News | Antiplatelet and Anticoagulation Therapies| January 11, 2017
For patients with atrial fibrillation, the most common form of heart arrhythmia, a main goal of treatment is stroke...
Avinger, Lightbox L250 imaging console, upgrade, Lumivascular platform, OCT, optical coherence tomography
Technology | Intravascular Imaging| January 11, 2017
January 11, 2017 — Avinger Inc. recently announced the U.S.
BioVentrix, Revivent TC Transcatheter Ventricular Enhancement System, LIVE procedure, first in Germany
News | Heart Failure| January 10, 2017
BioVentrix Inc. announced in December the first closed-chest Revivent TC TransCatheter Ventricular Enhancement System...
Overlay Init